Kepivance (Amgen Inc)

Kepivance (Amgen Inc) - General Information

Human keratinocyte growth factor (KGF), 140 residues long, expressed in E. coli. First 23 residues removed to improve stability.

Pharmacology of Kepivance (Amgen Inc)

Used in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.

Additional information about Kepivance (Amgen Inc)

Kepivance (Amgen Inc) Indication: For treatment of mucositis (mouth sores)
Mechanism Of Action: Kepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Palifermin
Synonyms: FGF-7; Fibroblast growth factor- 7; HBGF-7; KGF; Keratinocyte growth factor precursor
Drug Category: Antimucositis Agents
Drug Type: Biotech; Approved

Other Brand Names containing Palifermin: Kepivance (Amgen Inc);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Kepivance (Amgen Inc): Powder, for solution Intravenous
Chemical IUPAC Name: Human keratinocyte growth factor
Chemical Formula: C721H1142N202O204S9
Palifermin on Wikipedia: https://en.wikipedia.org/wiki/Palifermin
Organisms Affected: Humans and other mammals